In8bio Inc (INAB) - News Archive

Expanding Horizons in Cancer Immunotherapy: IN8bio Welcomes The Ohio State University to the INB-100 Phase 1 Clinical Trial The pursuit of innovative cancer treatments takes another encouraging stride as IN8bio, a promi...

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical firm based in New York, has announced the launch of its next-generation T cell-based T cell engager (TCE) platform, named INB-600. This pioneering technolo...

The landscape of leukemia treatment is undergoing significant evolution, particularly with the advent of innovative cell therapies. One company at the forefront of this paradigm shift is IN8bio, which has made remarkabl...

IN8bio Announces Promising Outcomes in Phase 1 Trial of INB-200, Highlighted at Society for Neuro-Oncology Annual Meeting IN8bio, a burgeoning leader in the development of innovative cancer therapies, recently presented...

IN8bio s Strategic Prioritization: Focusing on INB-100 for Acute Myeloid Leukemia amidst Market ChallengesIn a recent announcement, IN8bio Inc unveiled its clinical pipeline prioritization strategy, with an emphasis on...

Clinical Advancements in Gamma-Delta T Cell Therapy: IN8bio s Breakthroughs in OncologyRecent developments in the field of oncology have seen IN8bio, a leader in gamma-delta T cell therapy, make significant strides in t...

In recent groundbreaking presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the American Association for Cancer Research (AACR) 2024, IN8bio, a leading biotechnology company, has s...

The emerging field of precision medicine holds tremendous promise for revolutionizing cancer treatment. In this article, we delve into the latest groundbreaking developments presented by IN8bio at the highly anticipated...

In the realm of cancer therapy, the pursuit of innovative and effective treatments has been relentless. Over the years, immunotherapy has emerged as a promising avenue, with the potential to revolutionize the way we com...

Cancer continues to be a major global health concern, with conventional treatment options often falling short in delivering effective outcomes. However, the field of cancer immunotherapy has gained promising momentum in...

Glioblastoma, a highly aggressive form of brain cancer, has long been a challenging condition to treat effectively. However, there is new hope on the horizon as IN8bio, Inc. announces a groundbreaking gamma-delta T cell...

Over the past few years, IN8bio, Inc. (NASDAQ: INAB), a commendable trailblazer in the clinical-stage biopharmaceutical landscape, has made significant strides in developing innovative gamma-delta T-cell therapies. The...

IN8bio, a leading clinical-stage biopharmaceutical company specializing in innovative gamma-delta T cell therapies, has announced that it will be hosting a conference call on Tuesday, December 12, 2023, at 8:30 am ET. T...

IN8bios INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed GlioblastomaGlioblastoma (GBM) is an aggressive form of brain cancer with an incredibly poor prognosis. It is the most com...